OptiBiotix Health PLC Non-exclusive distribution agreement for SlimBiome (7468C)

TIDMOPTI

RNS Number : 7468C

OptiBiotix Health PLC

03 October 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Non-exclusive distribution agreement for SlimBiome(R)

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a non-exclusive agreement with Formulation Creations ("Formulation") to distribute OptiBiotix's SlimBiome(R) proprietary weight management technology in South Africa.

Formulation is a fast-growing South African ingredient solutions company, specialising in the formulation and supply of world class flavour and ingredients into the food manufacturing, health and sports nutrition sectors. They are the exclusive distributor in South Africa for Gold Coast Ingredients, Real Stevia, and Cambridge Commodities (OptiBiotix's UK distributor for SlimBiome(R)).

The agreement continues OptiBiotix's strategy of expanding SlimBiome(R) and SlimBiome (R) related products; like its own brand GoFigure(R) products; into global markets. South Africa represents a new opportunity in a growing market where the latest South African Demographic and Health Survey (2017) identified almost 70% of South African women are either overweight or obese. SlimBiome(R) is a patented formulation developed by experts in nutrition using ingredients shown to reduce weight in human studies. Independent human studies at a number of universities have shown SlimBiome(R) reduces hunger and cravings for sweet, fatty and savoury foods, leading to an average 2-3lb per week weight loss.

Formulation CEO Gary Coulson commented: "We are very excited to be working with OptiBiotix within our local market. Their portfolio of cutting-edge ingredients fits perfectly into our existing product range and offering strategy. We look forward to marketing their new science-based microbiome solutions to perspective health and nutrition product manufacturers."

Christina Wood, Sales & Marketing Director of OptiBiotix added: "Formulation is led by Gary Coulson, an industry expert with an extensive network of customers and partners in the South African market. With such a wealth of local knowledge and technical expertise in the health and wellness sector, we are in a great position to offer the South African market bespoke concepts and weight management products to meet the demands of the local population."

For further information, please contact:

 
 OptiBiotix Health plc                                           www.optibiotix.com 
 Stephen O'Hara, Chief Executive                               Contact via Walbrook 
                                                                              below 
 
 Cairn Financial Advisers LLP (NOMAD)                            Tel: [phone] 
 Liam Murray / Jo Turner 
 
   finnCap (Broker)                                              Tel: [phone] 
 Geoff Nash/ Scott Mathieson / Kate Bannatyne 
  (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 
 Walbrook PR Ltd                    Tel: [phone] or [e-mail] 
 Anna Dunphy                                                     Mob: [phone] 
 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

AGRGMMGGKZKGRZM

(END) Dow Jones Newswires

October 03, 2018 02:00 ET (06:00 GMT)